Roberto Cauda

Q: What Schools Are Affiliated With Roberto Cauda

Roberto Cauda is affiliated with the following schools: University of Milan, University of Turin, Università Cattolica del Sacro Cuore

Roberto Cauda's AcademicInfluence.com Rankings

Roberto Cauda

Engineering

#6075

World Rank

#7375

Historical Rank

Cybernetics

#117

World Rank

#123

Historical Rank

Biomedical Engineering

#507

World Rank

#517

Historical Rank

Applied Physics

#1889

World Rank

#1922

Historical Rank

engineering Degrees

Download Badge

Engineering

Roberto Cauda's Degrees

Masters Biomedical Engineering University of Milan
Bachelors Biomedical Engineering University of Turin

Why Is Roberto Cauda Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Roberto Cauda's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of chloroquine on viral infections: an old drug against today's diseases (2003) (1166)
Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. (2012) (875)
Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. (1996) (519)
New insights into the antiviral effects of chloroquine (2006) (509)
Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. (2007) (419)
Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. (2015) (419)
Predictors of Mortality in Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae: Importance of Inadequate Initial Antimicrobial Treatment (2007) (411)
Biofilm Production by Candida Species and Inadequate Antifungal Therapy as Predictors of Mortality for Patients with Candidemia (2007) (342)
Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae: Risk Factors, Molecular Epidemiology, and Clinical Outcome (2006) (294)
Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA) (2002) (248)
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients (2011) (232)
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase–producing K. pneumoniae (2018) (226)
In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. (1999) (217)
Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy (2020) (212)
Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy (2001) (210)
Improving empirical antibiotic treatment using TREAT, a computerized decision support system: cluster randomized trial. (2006) (188)
Costs of Bloodstream Infections Caused by Escherichia coli and Influence of Extended-Spectrum-β-Lactamase Production and Inadequate Initial Antibiotic Therapy (2010) (183)
Risk Factors and Outcomes of Candidemia Caused by Biofilm-Forming Isolates in a Tertiary Care Hospital (2012) (177)
Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. (2007) (176)
Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay. (2006) (175)
Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study. (2014) (168)
Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study. (2015) (157)
Identifying Patients Harboring Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae on Hospital Admission: Derivation and Validation of a Scoring System (2011) (152)
Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. (1999) (146)
Rapid screening tests for meticillin-resistant Staphylococcus aureus at hospital admission: systematic review and meta-analysis. (2009) (140)
Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. (2009) (140)
HIV infection, HAART, and endothelial adhesion molecules: current perspectives. (2004) (138)
Candida and candidiasis in HIV-infected patients: where commensalism, opportunistic behavior and frank pathogenicity lose their borders (2012) (138)
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study (2020) (135)
Antibiotic Usage and Risk of Colonization and Infection with Antibiotic-Resistant Bacteria: a Hospital Population-Based Study (2009) (131)
Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase- Producing Escherichia coli: Risk Factors for Inadequate Initial Antimicrobial Therapy (2008) (124)
Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality (2011) (122)
Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. (2007) (118)
Reduced Rate of Diagnostic Positive Detection of JC Virus DNA in Cerebrospinal Fluid in Cases of Suspected Progressive Multifocal Leukoencephalopathy in the Era of Potent Antiretroviral Therapy (2005) (118)
Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemia. (2012) (116)
Prosthetic joint infection: recent developments in diagnosis and management. (2010) (116)
Off‐label use of tocilizumab in patients with SARS‐CoV‐2 infection (2020) (113)
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing (2014) (112)
Anti-HIV Effects of Chloroquine: Inhibition of Viral Particle Glycosylation and Synergism With Protease Inhibitors (2004) (111)
The impact of bacteraemia on HIV infection. Nine years experience in a large Italian university hospital. (1995) (101)
Multidrug-Resistant Pseudomonas Aeruginosa Bloodstream Infections: Analysis of Trends in Prevalence and Epidemiology (2002) (98)
New classification for the treatment of pyogenic spondylodiscitis: validation study on a population of 250 patients with a follow-up of 2 years (2017) (98)
Infection control and prevention measures to reduce the spread of vancomycin-resistant enterococci in hospitalized patients: a systematic review and meta-analysis. (2014) (96)
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study (2020) (93)
Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line (2020) (91)
Bacterial pneumonia in HIV-infected patients: analysis of risk factors and prognostic indicators. (1998) (89)
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study (2012) (88)
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (2020) (87)
Mitochondrial Membrane Hyperpolarization Hijacks Activated T Lymphocytes Toward the Apoptotic-Prone Phenotype: Homeostatic Mechanisms of HIV Protease Inhibitors (2003) (84)
Evaluation of the New VITEK 2 Extended-Spectrum Beta-Lactamase (ESBL) Test for Rapid Detection of ESBL Production in Enterobacteriaceae Isolates (2006) (84)
Cardiovascular risk factors and carotid intima‐media thickness are associated with lower cognitive performance in HIV‐infected patients (2013) (84)
Factors associated with mortality in bacteremic patients with hematologic malignancies. (2009) (82)
Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects. (2002) (81)
SARS‐CoV‐2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate? (2021) (80)
Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving Highly Active Anti Retroviral Therapy (2004) (77)
Risk factors and predictors of mortality of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in HIV-infected patients. (2002) (77)
Increased soluble markers of endothelial dysfunction in HIV-positive patients under highly active antiretroviral therapy. (2003) (76)
Evidence of a selective depletion of a CD16+ CD56+ CD8+ natural killer cell subset during HIV infection. (1995) (76)
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. (2009) (75)
Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits? (2011) (75)
Predictive Models for Identification of Hospitalized Patients Harboring KPC-Producing Klebsiella pneumoniae (2014) (73)
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) (2017) (71)
Older HIV-positive patients in the era of highly active antiretroviral therapy: changing of a scenario (2003) (68)
Sarilumab use in severe SARS-CoV-2 pneumonia (2020) (67)
ESBL-producing multidrug-resistant Providencia stuartii infections in a university hospital. (2004) (66)
Detecting risk and predicting patient mortality in patients with extended-spectrum β-lactamase-producing Enterobacteriaceae bloodstream infections. (2012) (65)
Central venous catheter-related sepsis in a cohort of 366 hospitalised patients (1997) (64)
Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With Recurrent Clostridioides difficile Infection Treated With Fecal Microbiota Transplantation or Antibiotics (2019) (64)
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping (2010) (64)
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. (2010) (63)
Relative tachycardia in patients with sepsis: an independent risk factor for mortality. (2007) (63)
Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection. (1996) (61)
Prevention and control of methicillin-resistant Staphylococcus aureus. (2009) (60)
Glycopeptide resistance among coagulase-negative staphylococci that cause bacteremia: epidemiological and clinical findings from a case-control study. (2001) (59)
Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. (2017) (59)
Prediction models to identify hospitalized patients at risk of being colonized or infected with multidrug-resistant Acinetobacter baumannii calcoaceticus complex. (2008) (57)
Multidisciplinary management of pyogenic spondylodiscitis: epidemiological and clinical features, prognostic factors and long-term outcomes in 207 patients (2018) (56)
Serum of healthy donors receiving granulocyte colony-stimulating factor induces T cell unresponsiveness. (1998) (55)
Revised Central Nervous System Neuropenetration-Effectiveness Score is Associated with Cognitive Disorders in HIV-Infected Patients with Controlled Plasma Viraemia (2013) (55)
Bacteremia in patients with hematological malignancies. Analysis of risk factors, etiological agents and prognostic indicators. (1997) (54)
Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome. (2008) (54)
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case–control study (2013) (54)
Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study. (2021) (54)
Risks and benefits of chloroquine use in anticancer strategies. (2006) (53)
Characteristics of Staphylococcus aureus Bacteraemia and Predictors of Early and Late Mortality (2017) (52)
The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis (2007) (51)
The role of oxidative imbalance in progression to AIDS: effect of the thiol supplier N-acetylcysteine. (1998) (51)
Transmembrane P-glycoprotein (P-gp/P-170) in HIV infection: analysis of lymphocyte surface expression and drug-unrelated function. (1995) (51)
Candidaemia in Patients with an Inserted Medical Device (2012) (50)
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, At (2013) (49)
Inhibition of normal human natural killer cell activity by human immunodeficiency virus synthetic transmembrane peptides. (1988) (47)
Comparison of expression vectors in Lactobacillus reuteri strains (2010) (47)
The electrostatic potential of the Omicron variant spike is higher than in Delta and Delta‐plus variants: A hint to higher transmissibility? (2021) (46)
Vancomycin versus cefazolin prophylaxis for cerebrospinal shunt placement in a hospital with a high prevalence of meticillin-resistant Staphylococcus aureus. (2008) (45)
Multidrug-Resistant Proteus mirabilis Bloodstream Infections: Risk Factors and Outcomes (2012) (45)
Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients (2007) (45)
Candidemia in HIV-Infected Subjects (1999) (44)
Induction of CD69 antigen on normal CD4+ and CD8+ lymphocyte subsets and its relationship with the phenotype of responding T-cells. (1999) (44)
Mortality in patients with early- or late-onset candidaemia (2012) (44)
Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. (2010) (43)
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study. (2015) (43)
Synthetic peptides corresponding to sequences in HIV envelope gp41 and gp120 enhance in vitro production of interleukin-1 and tumor necrosis factor but depress production of interferon-alpha, interferon-gamma and interleukin-2. (1991) (38)
Partial protective effect of CCR5-Delta 32 heterozygosity in a cohort of heterosexual Italian HIV-1 exposed uninfected individuals (2006) (38)
RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies (2020) (38)
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients. (2017) (38)
Nosocomial bloodstream infections in HIV-infected patients: attributable mortality and extension of hospital stay. (1998) (37)
Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR. (2011) (37)
HIV-associated bacteremia: how it has changed in the highly active antiretroviral therapy (HAART) era. (2000) (37)
Deep Salvage With Amprenavir and Lopinavir/Ritonavir: Correlation of Pharmacokinetics and Drug Resistance With Pharmacodynamics (2004) (36)
Effect of Aging and Human Immunodeficiency Virus Infection on Cognitive Abilities (2012) (36)
Comparison of cognitive performance in HIV or HCV mono-infected and HIV–HCV co-infected patients (2013) (36)
COVID-19 and intestinal inflammation: Role of fecal calprotectin (2020) (35)
Central venous catheters and bloodstream infection. (2000) (34)
Effect of highly active antiretroviral therapy on the incidence of bacterial pneumonia in HIV-infected subjects. (2000) (34)
Osteoarticular bacterial infections are rare in HIV-infected patients. 14 cases found among 4,023 HIV-infected patients. (1997) (34)
Cognitive reserve and neuropsychological functioning in older HIV-infected people (2016) (34)
Clostridium difficile-associated diarrhoea in patients with human immunodeficiency virus infection: a case-control study. (1995) (33)
Declining Prevalence of HIV-1 Drug Resistance in Treatment-Failing Patients: A Clinical Cohort Study (2007) (33)
Anti-retroviral therapy with protease inhibitors decreases virulence enzyme expression in vivo by Candida albicans without selection of avirulent fungus strains or decreasing their anti-mycotic susceptibility. (2004) (33)
Antiretroviral Neuropenetration Scores Better Correlate with Cognitive Performance of HIV-Infected Patients after Accounting for drug Susceptibility (2015) (32)
Prediction of specific pathogens in patients with sepsis: evaluation of TREAT, a computerized decision support system. (2007) (32)
Intracellular expression of P-170 glycoprotein in peripheral blood mononuclear cell subsets from healthy donors and HIV-infected patients. (1998) (32)
Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity. (2005) (31)
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial (2018) (31)
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial (2018) (31)
The Threshold Bootstrap Clustering: A New Approach to Find Families or Transmission Clusters within Molecular Quasispecies (2010) (30)
Flow cytometric detection of perforin in normal human lymphocyte subpopulations defined by expression of activation/differentiation antigens. (1998) (30)
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. (2011) (30)
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) (2014) (30)
Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab (2020) (30)
Characterization of a novel human surface molecule selectively expressed by mature thymocytes, activated T cells and subsets of T cell lymphomas (1999) (29)
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. (2012) (29)
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. (2012) (29)
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial (2017) (28)
Expression of P-170 glycoprotein sensitizes lymphoblastoid CEM cells to mitochondria-mediated apoptosis. (2001) (28)
Nosocomial bacterial pneumonia in human immunodeficiency virus infected subjects: incidence, risk factors and outcome. (2001) (28)
Gastric cryptosporidiosis complicating HIV infection: case report and review of the literature. (1997) (28)
Cardiovascular risk score change in HIV‐1‐infected patients switched to an atazanavir‐based combination antiretroviral regimen (2008) (28)
Evidence for mutations in SARS‐CoV‐2 Italian isolates potentially affecting virus transmission (2020) (28)
Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: A new clinical entity? (2004) (27)
Hospital-Acquired Candidemia in HIV-Infected Patients. Incidence, Risk Factors and Predictors of Outcome (2004) (27)
HIV‐Associated Bacteremia: How It Has Changed in the Highly Active Antiretroviral Therapy (HAART) Era (2000) (27)
Pneumothorax in HIV-infected patients: role of Pneumocystis carinii pneumonia and pulmonary tuberculosis. (1997) (27)
Lopinavir/Ritonavir or Efavirenz plus two Nucleoside Analogues as First-Line Antiretroviral Therapy: A Non-Randomized Comparison (2005) (27)
Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase–Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study (2021) (26)
Morbidity associated with central venous catheter-use in a cohort of 212 hospitalized subjects with HIV infection. (2000) (26)
Analysis of natural killer (NK) cell subsets defined by the expression of two novel surface antigens (EB6 and GL183) in AIDS and AIDS-related conditions. (1994) (26)
Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds. (2010) (26)
Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells. (2006) (25)
Congenital cytomegalovirus: Immunological alterations (1987) (25)
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction. (2011) (25)
On the use of chloroquine for chikungunya (2007) (25)
Multiple myeloma associated with Epstein‐Barr virus in an AIDS patient: A case report (1995) (25)
The value of electrostatic potentials of the spike receptor binding and N-terminal domains in addressing transmissibility and infectivity of SARS-CoV-2 variants of concern (2022) (25)
Dental care and HIV-infected individuals: are they equally treated? (2005) (25)
Impact of Highly Active Antiretroviral Therapy (HAART) on the Incidence of Bacterial Infections in HIV-Infected Subjects (2003) (24)
Human Rickettsia aeschlimannii infection: first case with acute hepatitis and review of the literature. (2016) (24)
In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin. (2002) (24)
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy. (2012) (24)
Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: Extended follow-up of an observational study (2001) (24)
Comparative analysis of prognostic indicators of aspergillosis in haematological malignancies and HIV infection. (1997) (23)
Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study (2016) (23)
HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART. (2001) (23)
Characterization of JC virus in cerebrospinal fluid from HIV-1 infected patients with progressive multifocal leukoencephalopathy: insights into viral pathogenesis and disease prognosis (2011) (23)
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study (2018) (23)
Fluconazole resistant oral candidiasis in HIV-infected patients. (1997) (22)
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy. (2016) (22)
Aspartic proteases of Plasmodium falciparum as the target of HIV-1 protease inhibitors. (2005) (22)
Lipid-lowering effect of tenofovir in HIV-infected patients. (2011) (22)
Sonographic Patterns of the Gallbladder in Acute Viral Hepatitis (1984) (22)
HIV-associated bacterial pneumonia in the era of highly active antiretroviral therapy. (1999) (22)
HIV‐Protease Inhibitors Contribute to P‐Glycoprotein Efflux Function Defect in Peripheral Blood Lymphocytes From HIV‐Positive Patients Receiving HAART (2001) (22)
Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment (2016) (21)
The Importance of Addressing Multidrug Resistance and Not Assuming Single-Drug Resistance in Case-Control Studies (2006) (21)
Initial antifungal strategy does not correlate with mortality in patients with candidemia (2016) (21)
Predictors of Mortality in Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae: Importance of Inadequate Initial Antimicrobial Treatment (2007) (21)
Multicentre study of antimicrobial resistance and antibiotic consumption among 6,780 patients with bloodstream infections (2006) (21)
Liability of Health Care Professionals and Institutions During COVID-19 Pandemic in Italy: Symposium Proceedings and Position Statement (2020) (21)
Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus (2018) (21)
Staphylococcus aureus infections. (1998) (21)
Consensus document on controversial issues in the treatment of complicated skin and skin-structure infections. (2010) (21)
Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. (2008) (21)
Demonstration of NK cell-mediated lysis of varicella-zoster virus (VZV)-infected cells: characterization of the effector cells. (1986) (21)
HIV Infection, Antiretroviral Therapy and Cardiovascular Risk (2010) (20)
Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine. (2007) (20)
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). (2015) (20)
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy. (2011) (20)
Impact of antibiotic stewardship on perioperative antimicrobial prophylaxis. (2016) (20)
Highly active antiretroviral therapy decreases the incidence of bacteremia in human immunodeficiency virus-infected individuals. (1998) (20)
Corynebacterium striatum bacteremia in a patient with AIDS. (1994) (20)
Predictors of Staphylococcus aureus pneumonia associated with human immunodeficiency virus infection. (1996) (20)
Teicoplanin-resistant coagulase-negative staphylococcal bacteraemia in patients with haematological malignancies: a problem of increasing importance. (1997) (20)
Highly active antiretroviral therapy decreases the incidence of visceral leishmaniasis in HIV-infected individuals. (2000) (19)
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) (2016) (19)
Pott's disease of the cervico-occipital junction in an AIDS patient. (1996) (19)
Role of polymorphonuclear leukocytes in infection by retroviruses with emphasis on the human immunodeficiency virus. (1990) (19)
Trimethoprim–sulfamethoxazole therapy for patients with carbapenemase-producing Klebsiella pneumoniae infections: retrospective single-center case series (2017) (19)
Role of Lymphocyte Multidrug Resistance Protein 1 in HIV Infection: Expression, Function, and Consequences of Inhibition (2005) (19)
Three-Year Clinical Outcomes of Resistance Genotyping and Expert Advice: Extended follow-up of the Argenta Trial (2005) (19)
Analysis of immune function in herpes zoster patients: demonstration and characterization of suppressor cells. (1987) (19)
Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures. (2010) (18)
Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data. (2014) (18)
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients (2014) (18)
SARS-CoV-2 shifting transmission dynamics and hidden reservoirs potentially limit efficacy of public health interventions in Italy (2021) (18)
Mitochondrial DNA Haplogroups and Incidence of Lipodystrophy in HIV-Infected Patients on Long-Term Antiretroviral Therapy (2012) (18)
First Italian Consensus Statement on Diagnosis, Prevention and Treatment of Cardiovascular Complications in HIV-infected Patients in the HAART Era (2006) (2007) (18)
Mid‐dosing interval concentration of atazanavir and virological outcome in patients treated for HIV‐1 infection (2010) (18)
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy (2013) (18)
Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells (2011) (17)
Immunological alterations associated with recurrent herpes simplex genitalis. (1989) (17)
HIV proteinase inhibitors: do they really work against Candida in a clinical setting? (2002) (17)
Lower hemoglobin levels in human immunodeficiency virus–infected patients with a positive direct antiglobulin test (DAT): relationship with DAT strength and clinical stages (2006) (17)
Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure (2011) (17)
Impairment of Recent Thymic Emigrants in HCV Infection (2005) (17)
Changes in Incidence and Risk Factors of Mycobacterium avium Complex Infections in Patients with AIDS in the Era of New Antiretroviral Therapies (2001) (17)
Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. (2012) (16)
Economic evaluation of HIV treatments: the I.CO.N.A. cohort study. (2004) (16)
Association of HIV-1 Replication Capacity With Treatment Outcomes in Patients With Virologic Treatment Failure (2007) (16)
Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy (2005) (16)
Ethical Criteria for the Admission and Management of Patients in the ICU Under Conditions of Limited Medical Resources: A Shared International Proposal in View of the COVID-19 Pandemic (2020) (16)
Interpretation systems for genotypic drug resistance of HIV-1 (2003) (16)
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy (2018) (16)
Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study (2021) (16)
Simplification to atazanavir/ritonavir plus lamivudine versus maintaining atazanavir/ritonavir+2NRTIs in virologically suppressed HIV-infected patients: 96-week data of the ATLAS-M trial (2016) (16)
Trends of hospitalisations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016 (2019) (15)
Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure (2008) (15)
Fluconazole-resistant Candida parapsilosis fungemia in a patient with AIDS. (1996) (15)
Patients with condyloma acuminatum exhibit decreased interleukin-2 and interferon gamma production and depressed natural killer activity (1987) (15)
Activation-associated mitochondrial hyperpolarization hijacks T cells toward an apoptosis-sensitized phenotype (2003) (15)
Azole Susceptibility Patterns and Genetic Relationship Among Oral Candida Strains Isolated in the Era of Highly Active Antiretroviral Therapy (2002) (15)
Risk factors for recurrence in patients with Clostridium difficile infection due to 027 and non-027 ribotypes. (2019) (14)
Beneficial effect of highly active antiretroviral therapy (HAART) in reducing both HIV viral load and monoclonal gammopathy (1999) (14)
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial (2014) (14)
Role of place of acquisition and inappropriate empirical antibiotic therapy on the outcome of extended-spectrum β-lactamase-producing Enterobacteriaceae infections. (2019) (14)
Attitudes and practices of dentists treating patients infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. (2009) (14)
Antibiotic appropriateness and adherence to local guidelines in perioperative prophylaxis: results from an antimicrobial stewardship intervention (2020) (14)
Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection (2011) (14)
T-cell imbalances and NK activity in varicella-zoster virus infections. (1987) (14)
Dental hygienists behaviour towards HIV-positive patients in highly active antiretroviral therapy era: a pilot survey. (2011) (14)
Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy (2011) (14)
Hemangiomas and other congenital malformations in infants exposed to antiretroviral therapy in utero. (2004) (13)
Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Naïve to Antiretroviral Therapy (2009) (13)
Long‐term follow‐up of nevirapine‐treated patients in a single‐centre cohort (2009) (13)
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. (2019) (13)
HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects. (2013) (13)
Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1. (2008) (13)
Antibodies against a β-glucan-protein complex of Candida albicans and its potential as indicator of protective immunity in candidemic patients (2017) (12)
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients. (2011) (12)
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients. (2016) (12)
Clostridium difficile-associated diarrhea in human immunodeficiency virus infection--a changing scenario. (1999) (12)
Baseline CD4+ T-cell Count and Cardiovascular Risk Factors Predict the Evolution of Cognitive Performance During 2-Year follow-up in HIV-Infected Patients (2015) (12)
Systematic clinical management of patients with candidemia improves survival. (2018) (12)
Treatment of skin and soft tissue infections due to community-associated methicillin-resistant Staphylococcus aureus in Europe: the role of trimethoprim-sulfamethoxazole0010. (2011) (12)
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group (2013) (11)
Hospital infection control in Europe: evaluation of present practice and future goals. (2004) (11)
A Murine, Bispecific Monoclonal Antibody Simultaneously Recognizing β-Glucan and MP65 Determinants in Candida Species (2016) (11)
Expression of the novel T cell activation molecule hpH4 in HIV-infected patients: correlation with disease status. (2000) (11)
Procalcitonin is useful in driving the choice of early antibiotic treatment in patients with bloodstream infections. (2018) (11)
Diminished interferon gamma production may be the earliest indicator of infection with the human immunodeficiency virus. (1987) (11)
HIV protease inhibitors prevent mitochondrial hyperpolarization and redox imbalance and decrease endogenous uncoupler protein-2 expression in gp 120-activated human T lymphocytes. (2005) (11)
Inhibition of lymphokine-activated killer activity during HIV infection: role of HIV-1 gp41 synthetic peptides. (1990) (11)
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance (2013) (11)
Pemphigus vulgaris in a human-immunodeficiency-virus-infected patient. (1998) (11)
New insights concerning methicillin-resistant Staphylococcus aureus disease. (2009) (11)
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study (2014) (10)
Bicyclic peptidomimetics targeting secreted aspartic protease 2 (SAP2) from Candida albicans reveal a constrained inhibitory chemotype. (2012) (10)
Resource-saving advice from an infectious diseases specialist team in a large university hospital: an exportable model? (2015) (10)
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART (2018) (10)
Verbal list learning and memory profiles in HIV-infected adults, Alzheimer’s disease, and Parkinson’s disease: An evaluation of the “cortical hypothesis” of NeuroAIDS (2017) (10)
Sphingosine 1-phosphate promotes antigen processing and presentation to CD4+ T cells in Mycobacterium tuberculosis-infected monocytes. (2007) (10)
Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals. (2015) (10)
Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1. (2009) (10)
P-170 glycoprotein (P-170) is involved in the impairment of natural killer cell-mediated cytotoxicity in HIV+ patients. (1995) (10)
Candidiasis and HIV-Protease Inhibitors: The Expected and the Unexpected (2004) (10)
The influence of hepatitis C virus coinfection on the risk of lipid abnormalities in a cohort of HIV-1-infected patients after initiation of highly active antiretroviral therapy. (2004) (10)
Immune function in heroin addicts. (1979) (10)
Nosocomial acquisition of methicillin-resistant Staphyloccocus aureus (MRSA) and extended-spectrum beta-lactamase (ESBL) Enterobacteriaceae in hospitalised patients: a prospective multicenter study (2012) (10)
Switching to Coformulated Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed Patients: Data From a Multicenter Cohort. (2015) (10)
Variability of Raltegravir Plasma Levels in the Clinical Setting (2013) (10)
A new, striking morphological alteration of P-glycoprotein expression in NK cells from AIDS patients. (1998) (10)
Quinoline antimalarials as investigational drugs for HIV‐1/AIDS: in vitro effects on HIV‐1 replication, HIV‐1 response to antiretroviral drugs, and intracellular antiretroviral drug concentrations (2006) (10)
Psychopathological profile in COVID-19 patients including healthcare workers: the implications. (2020) (10)
Risk scoring and bloodstream infections. (2007) (10)
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study. (2012) (9)
A 72-h intervention for improvement of the rate of optimal antibiotic therapy in patients with bloodstream infections (2017) (9)
Key questions in antiretroviral therapy: Italian Consensus Workshop (2005). (2006) (9)
Lymphocyte transformation test with rabbit liver specific lipoprotein (RLSP) in chronic active hepatitis. (1979) (9)
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection (2016) (9)
Performance evaluation of the (1,3)-β-D-glucan detection assay in non-intensive care unit adult patients (2018) (9)
Role of trimethoprim‐sulphamethoxazole in preventing HIV‐associated bacteraemia (1997) (9)
Differential induction of P-glycoprotein and MRP by rifamycins in T lymphocytes from HIV-1/tuberculosis co-infected patients. (2002) (9)
Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study. (2020) (9)
Decreased function of Fas in patients displaying delayed progression of HIV-induced immune deficiency. (2001) (9)
Psychological distress during the initial stage of the COVID-19 pandemic in an Italian population living with HIV: an online survey. (2021) (9)
CD16+CD56+CD8+ natural killer (NK) cells are decreased during HIV infection. (1997) (9)
Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials (2021) (8)
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre (2014) (8)
[Central venous catheter-related sepsis: one year experience in a large university hospital] (1999) (8)
Recurrent venous thrombosis in a patient with haemophilia A and HIV infection. (2002) (8)
Immune response to influenza A(H1N1)v in HIV-infected patients. (2014) (8)
How could we reduce antibiotic use in critically ill patients? (2011) (8)
Activation of natural killer cell function during interferon-alpha treatment of patients with condyloma acuminatum is predictive of clinical response. (1988) (8)
Aetiological factors related to a positive direct antiglobulin test result in human immunodeficiency virus‐infected patients (2006) (8)
White Paper: Bridging the gap between surveillance data and antimicrobial stewardship in the outpatient sector—practical guidance from the JPIAMR ARCH and COMBACTE-MAGNET EPI-Net networks (2020) (8)
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL. (2019) (8)
White Paper: Bridging the gap between surveillance data and antimicrobial stewardship in the outpatient sector—practical guidance from the JPIAMR ARCH and COMBACTE-MAGNET EPI-Net networks (2020) (8)
Age as a prognostic factor in AIDS (1996) (7)
Effective vancomycin therapy for Corynebacterium pseudodiphtheriticum endocarditis. (1987) (7)
Nursing home residence is associated with spread of Clostridium difficile ribotype 027 in central Italy. (2016) (7)
Secondary Pneumocystis carinii pneumonia prophylaxis with trimethoprim-sulphamethoxazole does not prevent bacterial pneumonia in HIV-infected persons. (1996) (7)
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. (2009) (7)
3-Year Efficacy and Durability of Simplification to Single Tablet Regimens: A Comparison between Co-Formulated Efavirenz/Emtricitabine/Tenofovir and Rilpivirine/Emtricitabine/Tenofovir (2017) (7)
Correlation Between Cidofovir-Associated Uveitis and Failing Immunorestoration During HAART (2003) (7)
Genetic and Structural Data on the SARS-CoV-2 Omicron BQ.1 Variant Reveal Its Low Potential for Epidemiological Expansion (2022) (7)
Generic antiretrovirals for the treatment of HIV: a novel challenge for Western countries? . (2017) (7)
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 (2021) (7)
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients (2017) (7)
[Viral hepatitis B and polymyositis. Description of a case of polymyositis associated with viral hepatitis B]. (1988) (7)
Peripheral blood mononuclear cells and regulatory T cells in acute viral hepatitis. (1985) (7)
A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads. (2006) (7)
Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients (2019) (7)
Low dose hydroxychloroquine is associated with lower mortality in COVID-19: a meta-analysis of 26 studies and 44,521 patients (2020) (7)
Women Facing HIV. Key Question on Women with HIV Infection: Italian Consensus Workshop (2009) (6)
Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar years: a cohort study. (2009) (6)
Natural killer activity against viral targets in cyclosporine-treated renal allograft recipients. (1988) (6)
Evolutionary Analysis of SARS-2-CoV: How Mutation of Non-Structural Protein 6 (NSP6) Could Affect Viral Autophagy (2020) (6)
Effects of antiretroviral therapy on tube-like network formation of human endothelial cells. (2007) (6)
People living with HIV in the CoVid-19 era: a case report. (2020) (6)
An emerging opportunistic infection in HIV patients: A retrospective analysis of 11 cases of pulmonary aspergillosis (1993) (6)
Evaluation of efficacy, pharmacokinetics and tolerability of peptidomimetic aspartic proteinase inhibitors as cream formulation in experimental vaginal candidiasis (2014) (6)
Is there a drug-drug interaction between darunavir/ritonavir and raltegravir? (2012) (6)
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis (2014) (6)
IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines. (2018) (6)
White Paper: Bridging the gap between surveillance data and antimicrobial stewardship in the animal sector—practical guidance from the JPIAMR ARCH and COMBACTE-MAGNET EPI-Net networks (2020) (6)
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop. (2005) (6)
Risk factors, nutritional status, and quality of life in HIV-infected patients with enteric salmonellosis. (1998) (6)
Genome-based comparison between the recombinant SARS-CoV-2 XBB and its parental lineages (2022) (6)
Tuberculosis significantly reduces the survival of patients with AIDS. (1997) (5)
[Visceral leishmaniasis in patients with AIDS. Description of 2 cases]. (1989) (5)
Recommendations for the inclusion of Fabry disease as a rare febrile condition in existing algorithms for fever of unknown origin (2017) (5)
Peculiar Variations of the Electrostatic Potential of Spike Protein N-terminal Domain Associated with the Emergence of Successive SARS-CoV-2 Omicron Lineages (2022) (5)
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: Predictors of virological response and drug resistance evolution in a multi-cohort study (2009) (5)
Cognitive impairment and cardiovascular disease related to alexithymia in a well-controlled HIV-infected population. (2019) (5)
Replication of varicella zoster virus in Raji cells. (1986) (5)
Safety of darunavir/ritonavir (DRV/r) in HIV-1-infected DRV/r-experienced and -naïve patients: analysis of data in the real-world setting in Italy (2014) (5)
Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patients (2004) (5)
Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort Experience (2019) (5)
Liver fibrosis is associated with cognitive impairment in HIV-positive patients (2014) (4)
Multicomponent vaccines to fight SARS-CoV-2 variants of concern (2021) (4)
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? (2019) (4)
TREAT: a system for balancing antibiotic treatment against development of drug resistance (2004) (4)
Results of randomized controlled trial on the impact of prolonged combination anti HCV treatment on relapse rate in HIV/HCV coinfected patients with HCVRNA negativization at the end of a 24–48 weeks course of treatment: The ROMANCE study (2008) (4)
Meningoencephalomyelitis caused by herpes simplex virus‐1 in a patient with idiopathic T CD4+ lymphocytopenia (1998) (4)
Pseudomonas aeruginosa causing nosocomial meningitis in neonates and children: overview of 15 cases within 10 years. (2007) (4)
Antiapoptotic activity by HIV protease inhibitors either alone or boostered. (2002) (4)
A real-time integrated framework to support clinical decision making for covid-19 patients (2022) (4)
Lamivudine‐based maintenance antiretroviral therapies in patients living with HIV‐1 with suppressed HIV RNA: derivation of a predictive score for virological failure (2019) (4)
Drug resistant Pseudomonas aeruginosa bacteremia in HIV-infected patients. (1995) (4)
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function (2022) (4)
A fuzzy relational system trained by genetic algorithms and HIV-1 resistance genotypes/virological response data from prospective studies usefully predicts treatment outcomes (2004) (4)
Condyloma acuminatum: Epidemiological, clinical and therapeutic aspects (1987) (4)
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine (2016) (4)
Immune response to rabbit liver-specific lipoprotein in acute viral hepatitis. (1980) (4)
SARS-CoV-2 shifting transmission dynamics and hidden reservoirs limited the efficacy of public health interventions in Italy (2020) (4)
Evaluation of the antiretroviral effects of a PEG-conjugated peptide derived from human CD38. (2009) (4)
Shortening Epitopes to Survive: The Case of SARS-CoV-2 Lambda Variant (2021) (4)
Declining tuberculosis and drug resistance rate among HIV-positive patients at an Italian teaching hospital in the era of highly active antiretroviral therapy. (2002) (3)
Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering (2021) (3)
Antiphospholipid Antibodies in Chronic Active Hepatitis: Lack of Correlation with Anti-DNA Antibodies (1985) (3)
Genetic and structural genome-based survey reveals the low potential for epidemiological expansion of the SARS-CoV-2 XBB.1.5 sublineage (2023) (3)
Screen or not to screen? 7 questions in prevention of infection from refugees and migrants (2016) (3)
Challenges in COVID-19: is pulmonary thromboembolism related to overall severity? (2020) (3)
International infectious diseases teaching to undergraduate medical students: A successful European collaborative experience* (2017) (3)
Liver fibrosis is associated with cognitive impairment in people living with HIV (2019) (3)
The evolution of Monkeypox virus: a genetic and structural analysis reveals mutations in proteins involved in host-pathogen interaction (2022) (3)
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study. (2016) (3)
COVID-19 atypical Parsonage-Turner syndrome: a case report (2022) (3)
Antibiotic stewardship from toolkit to local implementation: the 'gutta cavat lapidem' strategy. (2017) (3)
Derivation and validation of a scoring system to assess pre-test probability of being COVID-19 positive (2020) (3)
Lack of correlation between HLA-DR and CD25 "activation" related antigens on CD16+ NK cells in HIV infection. (1997) (3)
Declining Prevalence of HIV-1 Drug Resistance in Treatment-Failing Patients: A Clinical Cohort Study (2007) (2)
Hiv Infection , Antiretroviral Therapy (2012) (2)
Ten years of brucellosis in Italy (1977–1986) (1988) (2)
A computerized decision support system (TREAT) to reduce inappropriate antibiotic therapy of bacterial infection (2004) (2)
The need to continue testing for HIV, even during the coronavirus disease 2019 (COVID‐19) pandemic (2020) (2)
Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: Prevalence and predictors (2007) (2)
Meningococcal meningitis in Italy: 1887–1986 (2004) (2)
[Natural killer (NK) activity in patients with HIV infection]. (1988) (2)
Detection of P-glycoprotein efflux activity on peripheral blood lymphocyte subsets from HIV+ patients. (1997) (2)
Surface P-glycoprotein expression on peripheral lymphocyte subpopulations from HIV-infected patients. (1997) (2)
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk (2014) (2)
Post-therapy viral set-point abatement following combined antiproliferative and immune-boosting interventions: results from a randomised clinical trial (2019) (2)
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults (2019) (2)
Non-AIDS-defining neoplasms and HIV infection. (1999) (2)
Circulating immune complexes in hodgkins disease (1980) (2)
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK (2016) (2)
Prevalence of Sexually Transmitted Infections and Factors Associated with HIV Status Among Vulnerable Women in Northern Uganda: Baseline Results from Pe Atye Kena Cohort Study (2021) (2)
[Bacterial pneumonia in HIV-infected patients] (1999) (2)
Predictors of mortality among adult, old and the oldest old patients with bloodstream infections: An age comparison. (2021) (2)
HCV co-infection does not affect the TREC/IL-7 pathway in HIV disease. (2008) (2)
High rate of Quantiferon positive and tuberculin negative tests in infants born at a large Italian University Hospital in 2011: a cautionary hypothesis (2012) (2)
Case Report: Multifocal Tubercular Osteomyelitis of the Spine and Bilateral Dactylitis. (2019) (2)
Health-related quality of life (HRQoL) from HIV patients’ perspective: comparison of patient-reported outcome (PRO) measures among people living with hiv (PLWH) and other chronic clinical conditions (2022) (2)
[Meningococcal meningitis in Italy: 1887-1986]. (1990) (2)
HIV protease inhibitors reduce IL-2 release from normal human phytohaemagglutinin-activated T cells. (2001) (2)
Evaluation of the antiretroviral effects of a PEG-conjugated peptide derived from human CD38 (2009) (2)
A call to research: the relationship between SARS-2-CoV, ACE 2 and antihypertensives (2020) (2)
Control interventions for preventing spread of vancomycin-resistant enterococci (VRE) in hospitals (2008) (2)
Direct and serum-induced lymphocytotoxicity against rabbit hepatocytes in chronic active hepatitis. (1981) (1)
No evidence of SARS-CoV-2 circulation in HIV-infected patients between December 2019 and February 2020 in Rome, Italy (2020) (1)
Ophthalmic artery resistance index is increased in HIV-Infected patients and is influenced by protease inhibitors exposure. (2014) (1)
Overview on the use of synthetic peptides in human immunodeficiency virus infection. (1988) (1)
HIV-1 Non-R 5 Co-receptor Tropism is Associated with a Larger Size of the Viral Reservoir but not with a Higher Risk of Virological Rebound in Patients on Effective Antiretroviral Therapy (2015) (1)
A pilot experience of common European infectious diseases curriculum for medical students: the IDEAL summer school. (2019) (1)
P858 Beta-lactam alone compared to β-lactam-macrolide combination therapy for community-acquired pneumonia: prospective, observational study using a propensity score (2007) (1)
Cutting epitopes to survive: the case of lambda variant (2021) (1)
Atazanavir (ATV) plasma concentrations at different times after drug uptake: associations with virologic response and hyperbilirubinemia (2008) (1)
Knowing more about chloroquine/hydroxycloroquine in COVID-19 patients (2020) (1)
Health emergencies during flights (Case reports and Mini-review) (2017) (1)
Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor–Based Regimen: The “STORE” Study (2020) (1)
Immunologic abnormalities and antibodies to HTLV-III in asymptomatic drug addicts. (1987) (1)
Single-tablet regimen is associated with reduced efavirenz withdrawal in antiretroviral naïve or switching for simplification HIV-infected patients (2012) (1)
Corrigendum to “Imatinib interferes with survival of multi drug resistant Kaposi's sarcoma cells” [FEBS Lett. 581 (2007) 5897–5903] (2008) (1)
Has COVID-19 changed the approach to HIV diagnosis? (2021) (1)
The role of procalcitonin outside of the Intensive Care Unit (ICU): a multidisciplinary approach. (2019) (1)
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance (2013) (1)
Follow-up of circulating immune complexes in the course of acute viral hepatitis, and correlation with serologically relevant parameters. (1984) (1)
Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction? (2009) (1)
Old and New Tools in the Diagnosis of Central Venous Catheter-Related Bloodstream Infections: Is there a Role for Brushing? (2004) (1)
Chloroquine/hydroxycloroquine and COVID-19: need to know more about (2020) (1)
Attitudes and practices of dentists treating HIV patients in HAART era. (2009) (1)
Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care centre: Results of the Telepass project (2021) (1)
Gram-negative bacillary meningitis in adults. (1995) (1)
The SARS‐CoV‐2 Mu variant should not be left aside: It warrants attention for its immuno‐escaping ability (2022) (1)
Gene Xpert MTB/RIF assay confirms its value in the first multicentre, randomised, controlled trial conducted in primary-care settings in Africa (2014) (1)
Detection of parasite related antigens associated with conglutinin binding immune complexes in patients with Schistosoma haematobium. (1988) (1)
Dental care and HIV-infected individuals: are they equally (2005) (0)
[A case of Corynebacterium pseudodiphteriticum (hofmannii) endocarditis]. (1987) (0)
Smoking, female gender and PI use are associated with decreasing renal function in TDF-containing HAART (2010) (0)
TABLE 1. Predictors of Atherogenic Lipid Profile According to NCEP Thresholds (Results From Separate Multivariate Logistic Regression Models) (2004) (0)
OC.03.4 DECREASE OF BLOODSTREAM INFECTION RATES IN PATIENTS WITH CLOSTRIDIUM DIFFICILE INFECTION TREATED WITH FAECAL MICROBIOTA TRANSPLANTATION: A PROSPECTIVE OBSERVATIONAL COHORT STUDY (2019) (0)
Initial antifungal strategy does not correlate with mortality in patients with candidemia (2015) (0)
825 RESULTS OF A RANDOMIZED CONTROLLED TRIAL ON THE IMPACT OF PROLONGED COMBINATION ANTI-HCV TREATMENT IN HIV/HCV CO-INFECTED PATIENTS (2008) (0)
Beta-lactam alone compared to ß-lactam-macrolide combination therapy for community-acquired pneumonia (2007) (0)
GRAd-COV2 vaccine provides potent and durable immunity in a randomised placebo-controlled phase 2 trial (COVITAR) (2022) (0)
[Cases of typhoid fever caused by by chloramphenicol-resistant Salmonella typhi]. (1983) (0)
Missed linkage to care for patients with chronic hepatitis C virus infection in a tertiary care center: results of the telepass project (2020) (0)
"Anti-Ia reactivity in sera from patients with chronic active hepatitis (CAH)". (1987) (0)
Antithrombin III in acute viral hepatitis. (1985) (0)
SARS-CoV-2 shifting transmission dynamics and hidden reservoirs potentially limit efficacy of public health interventions in Italy (2021) (0)
[Clinical and therapeutic considerations of 8 cases of differentiated insurgent thyroid carcinoma in the pediatric age]. (1977) (0)
Delta hepatitis. An overview. (1986) (0)
Lymphocytotoxicity to rabbit hepatocytes in acute viral hepatitis. (1981) (0)
HIV Patients' Tracer for Clinical Assistance and Research during the COVID-19 Epidemic (INTERFACE): A Paradigm for Chronic Conditions (2022) (0)
Strategies for infection control of nosocomial Legionnaires' disease: four-year surveillance experience in a teaching hospital in Italy. (2006) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
Possible predictive parameters for the outcome of bacterial meningitis (1994) (0)
Spectrum of Humanitarian Assistance Interventions in Acute Physiotherapy and Nursing Refugee Health Unit (Original research) (2018) (0)
[Presentation of a case of medullary carcinoma of the thyroid gland (author's transl)]. (1977) (0)
Use of procalcitonin as a tool for antibiotic stewardship. (2019) (0)
Education Harmonization in Nursing and Social Work as Response to Vulnerable Patient/Client Groups in the new Candidate Member States – Solidarity from European Union (Note) (2019) (0)
Colonic histoplasmosis. (2023) (0)
[B viral hepatitis in aged subjects]. (1980) (0)
Do genetic polymorphisms associated with inflammation/lipodystrophy or endothelial damage predict carotid alterations in HIV+ subjects under cART? (2008) (0)
Psychological distress during the initial COVID-19 pandemic in an Italian cohort of people living with HIV: an online survey (2021) (0)
O _ 02 Efficacy of integrase strand transfer inhibitors in different HIV-1 subtypes (2016) (0)
Incidence of antibodies against rabbit liver specific lipoprotein (RLSP) in chronic active hepatitis. (1983) (0)
Radiological changes and circulating immune complexes in patients with urinary schistosomiasis. (1989) (0)
Prediction of bloodstream infections using TREAT: a causal probabilistic network for diagnosis and treatment of infections (2005) (0)
Identifying Patients Harboring Extended-Spectrum- (cid:1) -Lactamase-Producing Enterobacteriaceae on Hospital Admission: Derivation and Validation of a Scoring System (cid:1) (2011) (0)
Surveillance of nosocomial infections in a teaching hospital. II. Clinical and epidemio-logical aspects. (1980) (0)
Assessment of seasonal influenza vaccine effectiveness in patients from a central Italy reference hospital: pitfalls and intricacies from a pilot case-control study (2014) (0)
Oral Thrush and HIV Protease Inhibitors (1999) (0)
In Vitro and In Vivo Modulation of MDR1/P‐Glycoprotein in HIV‐Infected Patients Administered Highly Active Antiretroviral Therapy and Liposomal Doxorubicin (2002) (0)
Immunity and pathogenesis of tuberculosis. (1998) (0)
Cognitive reserve and neuropsychological functioning in older HIV-infected people (2016) (0)
ORAL THRUSH AND HIV PROTEASE INHIBITORS. AUTHORS' REPLY (1999) (0)
Opportunistic aerobic Gram-negative bacterial infections: incidence and correlation with antibiotic usage. (1981) (0)
Cell-mediated cytotoxicity to rabbit liver-specific lipoprotein in chronic active hepatitis (1982) (0)
TREAT: an electronic consultant for the clinical microbiologist (2004) (0)
Liver fibrosis may lower PSA levels: A further reason to be wary in prostate cancer screening in men with HIV? (2023) (0)
The Importance of Addressing Multidrug Resistance and Not Assuming Single-Drug Resistance in Case-Control Studies (2006) (0)
Mechanisms of HIV Protease Inhibitors the Apoptotic-Prone Phenotype : Homeostatic Hijacks Activated T Lymphocytes Toward Mitochondrial Membrane Hyperpolarization (2003) (0)
[Hepatitis and drug addiction: clinical and immunological studies]. (1979) (0)
Day 10 Post-Prescription Audit Optimizes Antibiotic Therapy in Patients with Bloodstream Infections (2020) (0)
We shall Start Health Intervention against Collateral Effect of Pandemic to Metabolic, Cardiovascular and Mental Health in Migrants, Children and Caregivers (2021) (0)
Joint, Soft Tissue and Wound Infections in Physiotherapy Patients from a Mobile Health Care Unit in a Refugee Camp in Northern Bosnia (2018) (0)
Antibodies against a β-glucan-protein complex of Candida albicans and its potential as indicator of protective immunity in candidemic patients (2017) (0)
Clinical and virological characteristics of HIV and HCV co-infected versus HCV monoinfected patients: A real-life evaluation in the PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort (2016) (0)
Resistance to antiretroviral drugs (2013) (0)
Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing HAART in a woman presenting with high-level HIV viremia at week 38 of pregnancy (2010) (0)
Comparison of two datamining techniques for determining the role of baseline protease mutations on the virologic response to ritonavir/saquinavir-containing regimens (2005) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
HEAD AND NECK CANCER IN HIV-INFECTED PATIENTS: ASSOCIATION OF HUMAN PAPILLOMAVIRUS (HPV) AND SQUAMOUS CELL CARCINOMA (1998) (0)
Effect of combination therapy containing a high dose carbapenem on mortality in patients with carbapenem-resistant infection (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
[Direct and induced lymphocytotoxicity to rabbit hepatocytes in chronic active hepatitis]. (1980) (0)
[Behavior of gamma-glutamyltranspeptidase in acute viral hepatitis]. (1983) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
The Biological Properties of the SARS-CoV-2 Cameroon Variant Spike: An Intermediate between the Alpha and Delta Variants (2022) (0)
Interleukin-2 reconstitutes natural killer activity in transplant recipients. (1989) (0)
["In vivo" and "in vitro" immunological monitoring in carcinoma of the uterine cervix]. (1982) (0)
Molecular In-Depth on the Epidemiological Expansion of SARS-CoV-2 XBB.1.5 (2023) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
Phenotypic heterogeneity of PHA-activated CD69+ lymphocytes: the expression of APO-1/FAS antigen (CD95) and perforins identifies different functional subsets. (1997) (0)
Evaluation of circulating immune complexes (C.I.C.) in endometrial cancer. (1986) (0)
Cyclosporine reversibly inhibits natural killer-cell activity. (1991) (0)
Predictive Models for Identiﬁcation of Hospitalized Patients Harboring KPC-Producing Klebsiella pneumoniae (2014) (0)
Antibiotic Prophylaxis for Enteryx™ Procedure: Preliminary Results (2005) (0)
Imported malaria in Italy: 1971-1991 (1994) (0)
Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study) (2023) (0)
Want a better way to control antibiotic resistance? Fight the corruption (2015) (0)
Effects of N-acetylcysteine on human peripheral blood monocytes differentation and HIV-1 replication (1996) (0)
415. Epidemiological Evaluation of Antibiotic Resistance and Subsequent Effect on Healthcare Resource Utilization among Subjects with Pseudomonas aeruginosa Infections in Italy (2022) (0)
A 72-h intervention for improvement of the rate of optimal antibiotic therapy in patients with bloodstream infections (2017) (0)
Dental care and HIV-infected individuals: are they equally (2005) (0)
[Methionine Se 75 in hepatic scintigraphic diagnosis]. (1976) (0)
Training of a fuzzy relational system by genetic algorithms for interpreting HIV-1 resistance genotypes using virologic response to salvage therapy from prospective clinical data (2004) (0)
Expression and function of P-glycoprotein in natural killer (NK) cells during HIV infection (1997) (0)
HIV Protease Inhibitors Prevent Mitochondrial Hyperpolarization and Redox Imbalance and Decrease Endogenous Uncoupler Protein-2 Expression in Gp120-Activated Human T Lymphocytes (2005) (0)
Psychological distress related to the COVID-19 epidemic in an Italian population of People Living with HIV: an online survey (2020) (0)
Antiplasmodial effects of HIV-1 protease inhibitors (2005) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Roberto Cauda?

Roberto Cauda is affiliated with the following schools:

Roberto Cauda's Academic­Influence.com Rankings

Roberto Cauda's Degrees

Why Is Roberto Cauda Influential?

Roberto Cauda's Published Works

Published Works

What Schools Are Affiliated With Roberto Cauda?

Roberto Cauda's AcademicInfluence.com Rankings